Screening

One of the reasons that people often receive a late prostate cancer diagnosis is because they may notice any signs. Most people do not notice any enlarged prostate symptoms until the cancer is advanced. There are a number of prostate cancer signs & symptoms a person may notice if he is in the advanced stages. Below is a list of prostate cancer symptoms: Prostate Cancer And The Urethra Prostate cancer affects the urethra and the bladder. That is why men who have prostate cancer are likely to have

the most commonly diagnosed cancer in men, in the U. S and most cases of prostate cancer have a good prognosis. Some of these cases can be aggressive and the death-rate is assessed to be 2.8%. The Prostate-specific antigen (PSA) test is used for screening for prostate cancer, to aid early detection and treatment. Prostate-specific antigen (PSA) test Prostate-specific antigen (PSA) is a protein produced by the prostate gland, found in the blood. Blood sample is utilized to check PSA levels

prostate cancer screening. (Sandiford & D’Errico, 2015, p.86) The Health Belief Model was constructed to help understand behavior and reasons for noncompliance with medical care and actions. Nurses and healthcare professionals can use the information to help develop a model regarding prostate cancer screening that will educate patients, promote health, help prevent disease

When we have diseases or don’t feel well, we tend to seek treatments and try to cure it as soon as possible. However, what if there is no reliable treatment or nearly no treatment available? Then, the only option is to do research. Life can be really difficult and no one wants any sickness or diagnosed with such a hard-to-cure disease like cancer. Prostate Cancer is a known cancer that happens to men only and a lot of men in the U.S are diagnosed with it, and happens to male’s reproductive system

Prostate cancer is now the most common cancer in men in the UK and the second highest cause of male cancer death. Yet despite its high prevalence it is also highly survivable, with figures from Cancer Research UK showing that 84 per cent of men diagnosed with the disease survive ten years or more following treatment. With such a high survival rate would be easy to assume that the needs of this patient group are being adequately met. But this isn’t the case, says specialist prostate cancer physiotherapist

Baldness is a common occurrence among men. It is typically regarded as something normal and not indicative of any kind of health condition, although it may cause psychological distress in the affected. However, scientists have discovered positive correlations between baldness and several pathologies. Male-pattern hair loss, as it is formally known in the medical realm, affects at least 50% of men in old age. Its causes are believed to be largely genetic. Recent studies have finally shed some light

Within a Single Institution Although there are many methods that help with diagnosing prostate cancer such as biomarkers and needle core biopsy, it is the practice patterns of different pathologists that in the end determine the diagnosis. This article explains how and why interobserver variability can affect the ability to diagnose prostate cancer. Additionally, it determines the outliers for immunohistochemistry work up. Immunohistochemistry is a method that can help aid the diagnosis of prostate

In 1853, J. Adams, a surgeon at The London Hospital, documented the first case of prostate cancer. This was discovered by a histological examination. He documented in his report that this condition was “a very rare disease.” (Adams, 1853) At that time it was not clear to track the trend of prostate cancer as it now poses as a significant health problem. “In the United States, it is the most commonly diagnosed cancer in men, with 180,000 new cases and about 31,000 deaths occurring annually.” (Greenlee

The ACS guidelines also recommend screening men who are at high risk as early as 40 years of age (black, relative that was diagnosed young, Braca 1 (breast cancer) 1 or Braca 2. However, the USPSTF advises against PCa screening concluding there is moderate certainty that the benefits of such screening do not outweigh the harms (Quaseem et al., 2013). In the case for PSA screening, PCa is the leading internal malignancy in US men and the second leading cause

advantage of free prostate cancer screening (Oliver, 2007). Current state of the science Today, prostate cancer is usually detected through screening, and there are two methods for early detection. The prostate-specific antigen test (PSA) is used, but there are